What the FDA labels say about taking them together
Lithium and ziprasidone
Ziprasidone's FDA label of July 20, 2026 names lithium in its drug interactions section; lithium's label does not name ziprasidone itself but warns about its class (Atypical antipsychotics). The ziprasidone label: “The risk is increased with concomitant use of other serotonergic drugs and with drugs that impair metabolism of serotonin, i.e., monoamine oxidase inhibitors (MAOIs).”
Check it at the source: the lithium FDA label on DailyMed (effective December 23, 2025, Glenmark Pharmaceuticals Inc., USA); the ziprasidone FDA label on DailyMed (effective July 20, 2026, Apotex Corp.).
What does the lithium label say about ziprasidone?
Lithium's label does not name ziprasidone itself; it warns about its class (Atypical antipsychotics):
Lithium label, drug interactionsMonitor for neurologic adverse reactions. Atypical and Typical Antipsychotic Drugs
Lithium label, drug interactionsReports of neurotoxic reactions in patients treated with both lithium and an antipsychotic, ranging from extrapyramidal symptoms to neuroleptic malignant syndrome, as well as reports of an encephalopathic syndrome in few patients treated with concomitant therapy [see Warnings and Precautions ( 5.5 )].
Source: FDA drug label (Lithium Carbonate), Glenmark Pharmaceuticals Inc., USA, effective December 23, 2025 (SPL set 63b3790f-a9b5-47f4-bae1-ddf8b43c13c1), via openFDA; the full label on DailyMed
What does the ziprasidone label say about lithium?
Ziprasidone label, drug interactionsRisk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. John’s Wort [see Contraindications ( 4.3 ), Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6.2 )].
Ziprasidone label, warnings and precautionsThe risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., monoamine oxidase inhibitors (MAOIs) [see Contraindications ( 4.3 ), Adverse Reactions ( 6.2 ), Drug Interactions ( 7.3 )].
Source: FDA drug label (ziprasidone hydrochloride), Apotex Corp., effective July 20, 2026 (SPL set ccfd5ba2-7271-f3dd-4c98-7418c1a4b54a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lithium | Ziprasidone | |
|---|---|---|
| Labeled for | Bipolar disorder | Bipolar disorder, Schizophrenia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.104 per capsule 300 mg capsule | $0.269 per capsule 20 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once